Canada’s drug and vaccine regulator mentioned on Friday that it was withholding the nation’s first cargo of the Johnson & Johnson vaccine to confirm its security and high quality.

Well being Canada, the regulator, mentioned on Tuesday that not one of the Johnson & Johnson vaccine, developed by the corporate’s Janssen subsidiary, had been made at an Emergent BioSolutions manufacturing unit in Baltimore which had discarded tens of millions of probably contaminated doses of AstraZeneca’s coronavirus vaccine.

However in a press release issued on Friday night, it mentioned that since then it has “realized {that a} drug substance produced on the Emergent web site was used within the manufacturing of the preliminary Janssen vaccines.”

The regulator mentioned that it’s now working with Janssen and the Meals and Drug Administration in the USA to ensure that the vaccines meet Canada’s requirements for “high quality, security and efficacy.”

It didn’t determine what a part of the vaccine got here from Emergent past saying that it was an “lively ingredient.” Nor did it determine the plant have been the vaccine was produced.

About 1.5 million doses of the AstraZeneca vaccine despatched to Canada by the Biden administration in early April were also produced at the Baltimore plant. Well being Canada mentioned final week that its assessment of that vaccine uncovered no issues or contamination.

Vaccine manufacturing on the plant has been suspended. As much as 15 million doses of the Johnson & Johnson vaccine made there have been thrown away as a result of contamination fears. Inspectors from the F.D.A. later discovered that Emergent didn’t absolutely examine the contamination and located issues with the manufacturing unit’s disinfection practices, it measurement and design, the way it dealt with uncooked supplies and educated its employees.

On Thursday, Emergent introduced that it had removed some of its senior managers. Robert Kramer, the chief government, acknowledged that the “lack of a batch for a viral contamination is extraordinarily severe” however mentioned that he hoped manufacturing would begin once more in Baltimore quickly.

The F.D.A. had earlier paused shipments of the Johnson & Johnson vaccine because it appeared into uncommon blood clots amongst younger girls who obtained the shot. That was lifted a week ago after a warning label in regards to the clotting problem was added.